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Standardized donor‐derived cell‐free DNA (dd‐cfDNA) testing has been introduced
into clinical use to monitor kidney transplant recipients for rejection. This report de‐
scribes the performance of this dd‐cfDNA assay to detect allograft rejection in sam‐
ples from heart transplant (HT) recipients undergoing surveillance monitoring across
the United States. Venous blood was longitudinally sampled from 740 HT recipients
from 26 centers and in a single‐center cohort of 33 patients at high risk for antibody‐
mediated rejection (AMR). Plasma dd‐cfDNA was quantified by using targeted ampli‐
fication and sequencing of a single nucleotide polymorphism panel. The dd‐cfDNA
levels were correlated to paired events of biopsy‐based diagnosis of rejection. The
median dd‐cfDNA was 0.07% in reference HT recipients (2164 samples) and 0.17% in
samples classified as acute rejection (35 samples; P = .005). At a 0.2% threshold,

Abbreviations: ACR, acute cellular rejection; AMR, antibody‐mediated rejection; AR, acute rejection; AUC, area under the curve; cfDNA, cell‐free DNA; CLIA, Clinical Laboratories
Improvements Act; dd‐cfDNA, donor‐derived cell‐free DNA; D‐OAR, Donor‐Derived Cell‐Free DNA‐Outcomes AlloMap Registry; LVEF, left ventricular ejection fraction; NPV, negative
predictive value; NR, no rejection; OPTN, Organ Procurement and Transplantation Network; PPV, positive predictive value.
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dd‐cfDNA had a 44% sensitivity to detect rejection and a 97% negative predictive
value. In the cohort at risk for AMR (11 samples), dd‐cfDNA levels were elevated 3‐
fold in AMR compared with patients without AMR (99 samples, P = .004). The stand‐
ardized dd‐cfDNA test identified acute rejection in samples from a broad population
of HT recipients. The reported test performance characteristics will guide the next
stage of clinical utility studies of the dd‐cfDNA assay.
KEYWORDS

biomarker, clinical research/practice, heart (allograft) function/dysfunction, heart
transplantation/cardiology

1 | I NTRO D U C TI O N

clinically validated to quantify the percentage of dd‐cfDNA in trans‐
plant recipients’ blood without the need for donor or recipient geno‐

Acute rejection (AR), including acute cellular rejection (ACR) and
antibody‐mediated rejection (AMR), continues to be a complica‐
1

tion after heart transplant (HT). AR is a major cause of hospi‐

typing.10 This assay was shown to detect ACR in HT in a multicenter
retrospective case‐control study10 and to detect active rejection in
kidney transplant in a prospective, multicenter trial.11

talization and graft dysfunction during the early years post HT.

This study is the first to report a large, prospective, multicenter

However, symptoms may develop late in the process of graft

clinical validation of the ability of a standardized dd‐cfDNA assay to

damage, which underscores the need for routine rejection sur‐

detect AR in HT recipients.

veillance. Endomyocardial biopsy remains the primary means for

We conducted the Donor‐Derived Cell‐Free DNA‐Outcomes

rejection monitoring, but it is associated with patient discomfort,

AlloMap Registry (D‐OAR) study to examine the characteristics of

expense, and potentially serious procedural complications. 2-4

dd‐cfDNA in a routine, clinical surveillance setting with HT recipi‐

Noninvasive peripheral gene expression testing via the AlloMap

ents at 26 centers across the United States. The objective of D‐OAR

assay (CareDx, Inc., Brisbane, CA) has been widely adopted for

was to determine the test performance of dd‐cfDNA for the detec‐

AR surveillance by HT centers in the United States. This gene

tion of ACR, AMR, and graft dysfunction.

expression assay can provide a high (>99%) negative predictive
value 5 and has proved to be useful for ruling out ACR. However,
the gene expression profiling test has a limited positive predic‐
tive value (PPV) for cellular rejection, and the assay was not de‐
signed to detect AMR. For these reasons, the development of a
more comprehensive, noninvasive assay for the surveillance of
AR (both ACR and AMR) remains of great interest and clinical
importance. 6

2 | M E TH O DS
2.1 | D‐OAR study design
The D‐OAR (NCT02178943) is an observational, prospective, multi‐
center registry that aimed to evaluate clinical outcomes in HT recipi‐
ents who were receiving regular allograft rejection surveillance.12

Donor‐derived cell‐free DNA (dd‐cfDNA), detected in the blood

The primary objective was to determine whether the dd‐cfDNA

of transplant recipients, has been proposed as a noninvasive marker

level in an HT recipient's blood can differentiate rejection from the

of graft injury, which can be caused by ACR as well as acute AMR.

absence of rejection, as determined by endomyocardial biopsy in‐

Early dd‐cfDNA studies were based on the hypothesis that AR

terpretation. Secondary objectives were to determine whether graft

causes cell death in the allograft, which leads to increased levels of

dysfunction in the absence of rejection is associated with increased

dd‐cfDNA in the recipient's bloodstream.

dd‐cfDNA levels and to characterize dd‐cfDNA levels in stable pa‐

Data from single‐center studies have shown that elevated dd‐

tients who have no evidence of AR.

cfDNA levels can detect AR after HT, and an increase in levels can

Eligible study subjects were HT recipients ≥ 15 years and >

7-9

occur before rejection is detected on endomyocardial biopsy.

55 days posttransplant who were undergoing AlloMap gene expres‐

Shotgun whole‐genome sequencing has been used to detect and

sion profiling for rejection surveillance. Multiorgan transplant recip‐

quantify dd‐cfDNA, but the complexity and cost of the analyses

ients were excluded.

limit its application as a clinically relevant surveillance tool. Targeted

Pretransplant and serial data after transplant, including

quantification of dd‐cfDNA provides a more rapid and cost‐effective

clinical status, hospitalizations, diagnostic tests (including en‐

surveillance strategy, but also requires genotyping of the transplant

domyocardial biopsies, AlloMap scores, and echocardiograms),

donor, which can be impractical.

immunosuppressive maintenance therapy and drug levels, and

More recently, a targeted amplification, next‐generation se‐
®

quencing assay (AlloSure ; CareDx, Inc.) has been analytically and

posttransplant adverse events, were collected. The D‐OAR study
included 26 HT centers in the United States.12 The primary study

16006143, 2019, 10, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/ajt.15339, Wiley Online Library on [01/11/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

2890

2891

outcomes were AR (ACR and AMR) and graft dysfunction, as de‐

Transplantation revised classification scheme for ACR13 and patho‐

fined here later.

logic diagnosis of AMR.14 Biopsy interpretation was performed by

Between July 2014 and September 2016, blood specimens were

the pathologist at the participating transplant center.

collected for quantification of dd‐cfDNA levels at each surveillance

The AR group was defined as transplant recipients whose blood

visit that occurred for AlloMap testing. The regular surveillance

samples indicated either ACR (grade 2R or 3R), AMR (pAMR grade

schedule for testing was determined by each participating center's

1, 2, or 3), or mixed rejection (satisfying the requirements of both

standard of care. Following a protocol amendment in September

ACR and AMR). For analysis by type of rejection, mixed rejections

2016 (through 2018), the dd‐cfDNA specimen was drawn only

were pooled with AMR. The no rejection (NR) group was defined as

when a patient had a clinical suspicion of rejection and a planned

recipients whose samples had no biopsy evidence of AR (ACR grade

“for‐cause” biopsy. Surveillance biopsies and biopsies performed for

0R or 1R and AMR grade pAMR0). The graft dysfunction group was

cause were analyzed separately in addition to the combined anal‐

defined as recipients whose blood samples had no biopsy evidence

ysis, to determine whether the 2 clinical settings render differing

of AR and who had ≥ 1 of the following: LVEF < 40% or a decrease

relationships with regard to cell‐free DNA. Two follow‐up dd‐cfDNA

of ≥ 25% from the prior visit.

specimens were collected within 8 weeks after “for‐cause” biopsies
in patients who were treated for rejection and/or graft dysfunction.

2.2 | Cedars‐Sinai study
A parallel single‐center study was conducted at Cedars‐Sinai Medical

2.5 | Reference population
The reference population was defined as all D‐OAR patients with
samples that did not indicate ACR (grade 2R or 3R), AMR (pAMR
grade 1, 2, or 3), or mixed rejection during the course of the study.

Center from March 2016 to May 2017. HT recipients identified as

For sensitivity, we also define a restricted population in which pa‐

high risk for the development of AMR were enrolled and followed

tients with samples with any ACR grade 1R as well as dd‐cfDNA

longitudinally. The inclusion criteria were pretransplant PRA ≥ 10%,

samples not paired with biopsy were excluded (146 patients [214

presence of donor‐specific antibodies at the time of transplant,

samples]).

any posttransplant detection of DSA or biopsy‐proved AMR, or
“for‐cause” biopsy due to reduced left ventricular ejection fraction
(LVEF). Samples were collected beginning 14 days posttransplant

2.6 | Statistical analyses

from patients 18 years or older. This cohort included 110 samples

The primary objective of the statistical analysis was to determine

from 33 patients and information on dd‐cfDNA and biopsy grades

whether the dd‐cfDNA level in an HT recipient's blood can differ‐

were collected for ACR and AMR. The objective of this study was

entiate AR from NR, as determined by local pathologists’ endomyo‐

to correlate dd‐cfDNA levels in patients with pAMR ≥ 1 in this inde‐

cardial biopsy diagnostic classification. Surveillance biopsies and

pendent sample set.

biopsies performed for cause were analyzed separately, to determine
whether the 2 clinical settings render differing relationships with re‐

2.3 | Blood samples and dd‐cfDNA measurements

gard to dd‐cfDNA testing. The blood was collected for dd‐cfDNA
assays within 3 days before endomyocardial biopsy. Wilcoxon rank

Venous blood was collected in Streck Cell‐Free DNA BCT tubes be‐

sum testing was used to compare dd‐cfDNA values associated with

fore the performance of endomyocardial biopsies and was shipped

AR with dd‐cfDNA values associated with NR. Further comparisons

to the central Clinical Laboratories Improvements Act–certified

were performed of ACR vs no ACR in patients without AMR, and of

laboratory at CareDx, Inc. Details of the standardized specimen

AMR vs no AMR. Performance characteristics of dd‐cfDNA to diag‐

processing and analytical methods to determine the percentage of

nose AR were computed, including sensitivity, specificity, PPV, and

dd‐cfDNA (AlloSure®) have been published.10 The targeted next‐

NPV.

generation sequencing assay uses highly polymorphic single nucleo‐

Additional analyses assessed the correlation of dd‐cfDNA to

tide polymorphisms to quantify dd‐cfDNA without the need for sep‐

graft dysfunction in the absence of AR. The graft dysfunction group

arate genotyping of the recipient or the donor.10 All measurements

and the no–graft dysfunction group were compared by using the

were performed by laboratory technicians unaware of the clinical

Wilcoxon rank sum test. An additional objective was to character‐

identity of the samples.

ize the reported values of dd‐cfDNA in the reference population,
including median levels and normal ranges.

2.4 | Diagnosis of graft dysfunction and of biopsy‐
defined rejection

Power calculations were performed as follows. An effect size
of 0.83 was estimated from a prior HT study of dd‐cfDNA in ref‐
erence cases of biopsy‐based AR compared with control cases

Information was collected on the number of, and clinical indica‐

with NR.10 We assumed that the [mean log(dd‐cfDNA) AR – [mean

tion for, endomyocardial biopsies for each patient. Biopsies were

log(dd‐cfDNA) NR]/(standard deviation of log (dd‐cfDNA)] = 0.83.

graded according to the International Society for Heart and Lung

Accordingly, there is a 90% power to demonstrate a significant
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A

A: 2164 samples from
676 patients for the
reference population
(no evidence of
rejection)

B: 841 samples from 443 patients paired
with biopsy
587 surveillance
254 for cause

C: 18 Antibody Mediated Rejection (AMR)
samples (pAMR1, pAMR2 or pAMR3) from 17
patients

E: 806 No Rejection samples from
424 patients
566 surveillance
240 for cause

12 surveillance
6 for cause

D: 17 Acute Cellular Rejection (ACR) samples
grade 2R or 3R with no AMR from 17 patients
9 surveillance
8 for cause

B

F: 2405 samples from 729 patients with no evidence of
rejection (includes samples with no biopsy)

G: 31 graft dysfunction
samples from 31 patients

H: 2374 no graft dysfunction
samples from 723 patients

C

I: 110 samples from 33 patients paired with biopsy

J: 11 Antibody Mediated
Rejection (AMR) samples
(pAMR1, pAMR2 or pAMR3)
from 5 patients

K: 99 pAMR0 samples from
31 patients

difference in dd‐cfDNA in 17 cases of AR compared with dd‐cfDNA
levels in 323 NR cases, from a total of 340 visits, assuming ACR

F I G U R E 1 CONSORT diagrams for
Donor‐Derived Cell‐Free DNA‐Outcomes
AlloMap Registry (D‐OAR). A, Reference
population (Box A) includes all 2164
D‐OAR samples from patients with no
clinical signs or symptoms of rejection and
no biopsy‐based evidence of rejection (no
rejection [NR] = no acute cellular rejection
[ACR] grade ≥ 2R or antibody‐mediated
rejection [AMR] grade ≥ pAMR1). Eight
hundred forty‐one samples (Box B) had
biopsy paired with donor‐derived cell‐free
DNA (dd‐cfDNA) results, of which 18 had
AMR, including 2 mixed rejections (Box C),
17 had ACR (Box D), and 806 had NR (ACR
grade 0R or 1R and AMR grade pAMR0,
Box E). B, The 2405 D‐OAR samples
that did not have a rejection diagnosis
(Box F) include 31 graft dysfunction
samples (left ventricular ejection fraction
[LVEF] < 40 or drop in LVEF of ≥ 25%
from previous visits, Box G) and 2374 no
graft dysfunction samples (Box H). C, The
110 samples from Cedars‐Sinai patients
(Box I) include 11 associated with biopsy
evidence of AMR (Box J) and 99 with NR
(Box K)

3.2 | Reference population

and/or AMR would be discovered at 5% of biopsy surveillance

The reference population (Table 1, Figure 1A, Box A) was com‐

visits.

posed of 676 patients who contributed 2164 samples and who had
no clinical signs or symptoms of AR during the course of the study.

3 | R E S U LT S
3.1 | D‐OAR patients

The mean age at enrollment was 54 years, 73% were > 50 years old,
75% were male, 70% were white, and the most common indications
for transplant were dilated cardiomyopathy (49%) and ischemic car‐
diomyopathy (32%). Patients were enrolled at a median of 170 days

From September 2014 to October 2017, 740 HT recipients were

posttransplant (IQR 116‐249 days), and 3 samples were drawn, on

enrolled at 26 clinical sites (Figure 1A; Table S1, participating sites)

average, per patient. This reference population is demographically

from which 2447 plasma dd‐cfDNA level samples were drawn.

similar to, but slightly older, than HT patients included in the Organ

Blood samples were drawn for dd‐cfDNA quantification from

Procurement and Transplantation Network data,15 who are 74% male

55 days to >5 years posttransplant. Most (81%) samples were

and 73% white, and 57% were > 50 years old at time of transplant.

drawn within the first year posttransplant, and 13% were drawn

The median dd‐cfDNA level in this reference population was

during the second year (Figure S1). Eight hundred forty‐one dd‐

0.07% (IQR 0.03%‐0.14%), as shown in Figure 2A. The 97.5th

cfDNA results were paired with a biopsy, of which 587 biopsies

percentile was 1.29%. Sensitivity analysis on the restricted pop‐

were performed for routine rejection surveillance and 254 biopsies

ulation (all samples from patients with any ACR grade 1R, as well

were “for cause” based on clinical suspicion (Table 1, Figure 1A).

as dd‐cfDNA samples not paired with biopsy, were excluded)
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TA B L E 1

Demographic and clinical characteristics of the reference population

Variable

Reference

All biopsies

NR

AR

No. of samples

2164

841

806

35

No. of patients

676

443

409

34

Samples per patient

3.2

1.9

2.0

1.0

Congenital

18 (3%)

13 (3%)

11 (3%)

2 (6%)

Pretransplant diagnosis

P (AR vs NR)

.201

Ischemic cardiomyopathy

216 (32%)

139 (31%)

125 (31%)

14 (41%)

Multiple

14 (2%)

10 (2%)

10 (2%)

0 (0%)

Nonischemic cardiomyopathy

329 (49%)

221 (50%)

209 (51%)

12 (35%)

Other

92 (14%)

55 (12%)

50 (12%)

5 (15%)

Retransplant

7 (1%)

5 (1%)

4 (1%)

1 (3%)

Race

.605

Asian

20 (3%)

9 (2%)

8 (2%)

1 (3%)

Black

112 (17%)

59 (13%)

54 (13%)

5 (15%)

White

474 (70%)

326 (74%)

303 (74%)

23 (68%)

Hispanic

50 (7%)

34 (8%)

31 (8%)

3 (9%)

Other

20 (3%)

15 (3%)

13 (3%)

2 (6%)

505 (75%)

330 (74%)

305 (75%)

25 (74%)

D−:R−

113 (17%)

70 (16%)

66 (16%)

4 (12%)

D−:R+

127 (19%)

76 (17%)

70 (17%)

6 (18%)

D+:R−

171 (25%)

122 (28%)

115 (28%)

7 (21%)

D :R

235 (35%)

147 (33%)

131 (32%)

16 (47%)

Unknown

30 (4%)

28 (6%)

27 (7%)

1 (3%)

326 (48%)

204 (46%)

184 (45%)

20 (59%)

Male sex
Cytomegalovirus serologic status

+

2893

+

.523

Mechanical support
None

.841

.381

Left ventricular assist device

297 (44%)

201 (45%)

189 (46%)

12 (35%)

Temporary circulatory support

42 (6%)

37 (8%)

35 (9%)

2 (6%)

Total artificial heart

11 (2%)

1 (0%)

1 (0%)

0 (0%)

Age at enrollment, y

54 ± 13

54 ± 12

54 ± 12

55 ± 13

LVEF at enrollment, %

59 ± 9

59 ± 9

59 ± 9

61 ± 7

Days posttransplant at enrollment

292 ± 537

299 ± 391

280 ± 311

523 ± 892

Height, cm

174.6 ± 9.9

175 ± 9.6

174.9 ± 9.7

176.2 ± 9.2

.495

Weight, kg

84.9 ± 18.3

86.7 ± 18.8

86.4 ± 18.4

90.7 ± 23.5

.221

.721
.393
0<0.001

AR, acute rejection; NR, no rejection; LVEF, left ventricular ejection fraction.

showed similar characteristics: the median dd‐cfDNA level was
0.07% (IQR 0.03%‐0.12%). There was no statistical difference
between the assessment of the reference population and the
restricted population (P = .925, Kolmogorov–Smirnov test). The

3.3 | Clinical events
3.3.1 | Rejection

levels of dd‐cfDNA in HT recipients’ blood remain very low and

Of the total of 841 endomyocardial biopsies performed in study

stable during the first 2 years posttransplant, in the absence of

subjects and paired with dd‐cfDNA, there were 17 biopsy‐

AR (Figure 2B, P = .182). The median dd‐cfDNA intrapatient vari‐

proved ACRs (grade 2R or 3R, no AMR), 18 AMRs (grade pAMR1

ability (CV I) is 70%, and the interpatient coefficient of variation

or pAMR2 including 2 mixed rejections), and 806 NR samples

(CVG) of patient median values is 86%, based on 350 patients

(Figure 1A, Boxes B‐E). The greatest number of biopsies (384) and

from the reference population who had at least 3 test results per

the most AR cases (14) occurred within the first 6 months post‐

patient.

transplant. Ten ARs were diagnosed in 279 biopsies performed
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A

Median: 0.07%
Interquartile Range: 0.03% - 0.14%
97.5th percentile: 1.29%

B

N:
Med:

57
0.07%

111
0.08%

379
0.06%

469
0.06%

565
0.07%

221
101
0.07% 0.08%

79
0.07%

53
0.08%

23
0.07%

F I G U R E 2 The donor‐derived cell‐free
DNA (dd‐cfDNA) levels in heart transplant
reference population. A, Analysis includes
2164 Donor‐Derived Cell‐Free DNA‐
Outcomes AlloMap Registry samples.
The median dd‐cfDNA level was 0.07%
(IQR, 0.03%‐0.14%). The 97.5th percentile
was 1.29%. B, The dd‐cfDNA levels by
time posttransplant. Levels of dd‐cfDNA
in the reference population are stable
from 55 days to 2 years posttransplant
(P = .182)

during months 6 through 12, 4 ARs occurred in 122 biopsies dur‐

97.1%. When examined by type of rejection, the PPV for ACR detec‐

ing year 2, and 4 additional ARs occurred in 51 biopsies during

tion was 4.8% with an NPV of 98.6%, whereas for AMR, the PPV was

years 3 to 5 posttransplant. Three additional AR cases were diag‐

4.2% and the NPV was 98.6%.

nosed in 5 biopsies after 5 years posttransplant.
The dd‐cfDNA levels differed significantly between patients
with and without AR (Figure 3A). The median level of dd‐cfDNA in

3.4 | Surveillance biopsy analysis

patients with AR was significantly higher (0.17%) than in the group

Of the 587 surveillance group samples, there were 21 ARs, including

of patient specimens without rejection (0.07%, P < .001). Median

9 ACRs and 12 AMRs. Each of these cases was from a unique pa‐

dd‐cfDNA levels were 0.17% for both ACR and AMR.

tient. The median level of dd‐cfDNA in surveillance samples paired

ACR grade 1R had a similar median level (0.08%) to grade

with rejection was 0.15% (IQR 0.04%‐0.23%) and 0.07% in samples

0 biopsies (0.07%), whereas ACR 2R (moderate) had a median

paired with NR (IQR 0.02%‐0.14%). The sample size was too small

dd‐cfDNA level of 0.15%, and ACR 3R (severe) had a median

to detect a statistically significant difference in median dd‐cfDNA

dd‐cfDNA level of 0.30% (Figure 3B). dd‐cfDNA levels differ‐

levels (P = .140, Figure 3D). Sensitivity was 38.1% (21.4%‐54.5%),

entiated ACR grade ≥ 2R (P = .004) from NR. Biopsies graded

specificity was 84.0% (81.2‐86.7%), PPV was 8.1% (4.7%‐11.9%),

as pAMR0 had median dd‐cfDNA levels of 0.07%, whereas the

NPV was 97.3% (96.7%‐98.0%), and AUC was 60.5% (46.0%‐74.2%)

median was 0.12% in pAMR1 and 0.25% in pAMR2 (Figure 3C).

for identifying rejection.

The fractions of true‐ and false‐positive results for dd‐cfDNA to
detect AR are shown in Figure S2. The area under the curve (AUC)
was 0.64 (95% confidence interval 0.52 to 0.75). With a cutoff of

3.5 | For‐cause biopsy analysis

0.2%, the dd‐cfDNA assay had 80% specificity and 44% sensitivity

Of the 254 “for‐cause” samples, there were 14 ARs, including 8 bi‐

to differentiate AR from NR. The PPV was 8.9%, and the NPV was

opsy‐proved ACRs from unique patients (ACR 2R or 3R) and 6 AMRs
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A

2895

p = 0.004

B
p = 0.005

N:
451
Med: 0.07%

35
0.17%

806
0.07%

N:
Med:

p = 0.249

C

N:
Med:

676
0.07%

3
0.30%

p = 0.104

D

14
0.12%

14
0.15%

355
0.08%

4
0.25%

N:
Med:

566
0.07%

9
0.12%

12
0.17%

p = 0.020

E

N:
Med:

240
0.09%

8
0.25%

6
0.74%

F I G U R E 3 The donor‐derived cell‐free DNA (dd‐cfDNA) level correlates with acute rejection (AR). A, Sample sizes and median dd‐cfDNA
levels for samples with (AR) and without (NR) AR. B, Sample sizes and median dd‐cfDNA levels by ACR grade, for patients not diagnosed
with AMR. C, Sample sizes and median dd‐cfDNA levels by AMR grade, including patients with mixed rejection. D, Sample sizes and median
dd‐cfDNA levels for samples associated with surveillance biopsy with NR, ACR grade ≥ 2R, and AMR grade ≥ pAMR1 (including mixed
rejection). E, Sample sizes and median dd‐cfDNA levels for samples associated with for‐cause biopsy with NR, ACR grade ≥ 2R, and AMR
grade ≥ pAMR1 (including mixed rejection)
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(pAMR1 or pAMR2). The median level of dd‐cfDNA in for‐cause

the patients: 25 patients had 53 grade 0R results and 22 patients

samples paired with rejection was 0.25% (IQR 0.10%‐0.31%) and

had 57 grade 1R results. Patients with pAMR1 or pAMR2 had

0.09% in samples paired with NR (IQR 0.04%‐0.19%). Statistically

higher median dd‐cfDNA levels (0.50%) than those with pAMR0

different median dd‐cfDNA levels were observed in patients with

(0.16%) (P = .004) (Figure 5). The dd‐cfDNA level of pAMR0 was

and without rejection (Figure 3E, P = .02). Sensitivity was 53.8%

more than double that observed for pAMR0 in D‐OAR; never‐

(33.3‐75.1%), specificity was 76.1% (71.6%‐80.2%), PPV was

theless, dd‐cfDNA could still differentiate patients with pAMR1

11.6% (7.6%‐16.6%), NPV was 96.6% (95.2%‐98.2%), and AUC was

or pAMR2 from those without AMR with sensitivity of 88.0%,

68.5% (48.0%‐86.4%) for identifying rejection.

specificity of 61.5%, PPV of 20.2%, and NPV of 97.9% at a thresh‐
old of 0.2%.

3.6 | Graft dysfunction
Thirty‐one graft dysfunction events paired with dd‐cfDNA occurred

4 | D I S CU S S I O N

in 31 unique study subjects (Figure 1B, Box F‐H). The dd‐cfDNA lev‐
els (median 0.07%) were not significantly different from the median

This report presents the results of a large, multicenter, prospective

levels in the reference population. However, when the %dd‐cfDNA

study that was designed to establish the performance characteris‐

is plotted against either LVEF or LVEF change, those with lowest

tics of a well‐validated, fully standardized dd‐cfDNA assay in a broad

LVEF generally had the highest dd‐cfDNA levels (Figure 4). Of those

population of HT recipients in the United States. The size and design

with both low LVEF and a ≥ 25% reduction of LVEF from the prior

of the study estimated that the number of AR events was sufficient

visit (red circles in Figure 4), the median dd‐cfDNA value was 0.53%

to demonstrate statistically significant performance characteristics

(n = 8, P = .007 compared with no AR or graft dysfunction; clinical

of the assay. Critically, the dd‐cfDNA measurement is an analytically

details are given in Table S2).

validated assay in a College of American Pathologists‐accredited,
CLIA‐certified reference laboratory.10

3.7 | Cedars‐Sinai study

In the study population of patients who had received an HT at
least 55 days before enrollment, dd‐cfDNA testing detected AR with

Among 110 samples from 33 patients in the Cedars‐Sinai study,

an AUC of 0.64 and provided an estimated NPV of 97.1% and PPV of

there were 99 samples from 33 patients with pAMR0, 3 sam‐

8.9%. These results, from a contemporary HT patient population that

ples from 3 patients with pAMR1, and 8 samples from 3 patients

includes patients with both ACR and AMR, validate prior reports of the

with pAMR2 (Figure 1C, Box I‐K). Sixty‐seven percent of the

performance characteristics of this assay in a population in which only

patients were nonwhite, and the average age was 56 years. The

ACR was characterized.10 We demonstrated that dd‐cfDNA levels are

patients with AMR were younger than those without AMR (47 vs

significantly higher in patients with AR compared with patients with

58 years). Moderate or severe ACR was not diagnosed in any of

no biopsy evidence of rejection. The current report is strengthened

F I G U R E 4 Association of donor‐derived cell‐free DNA (dd‐cfDNA) with graft dysfunction without biopsy evidence of rejection. Thirty‐
one patient samples with either no biopsy or no acute rejection (grade 0 or grade 1R acute cellular rejection and pAMR0) within 3 days of
the dd‐cfDNA sample. Graft dysfunction was defined as left ventricular ejection fraction (LVEF) < 40% (green cross, n = 12, median 0.07%), a
drop in LVEF ≥ 25% from the prior visit (blue triangle, n = 11, median 0.08%), or both (red circle, n = 8, median 0.53%). Left, LVEF. Right, drop
in LVEF. One patient (without a time‐matched biopsy) had dd‐cfDNA of 1.4% measured 4 days before a biopsy revealed grade 3R rejection
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In the reference population of stable HT recipients free of rejec‐
tion, dd‐cfDNA is present at very low levels (median 0.07%). This is in
contrast to stable kidney transplant recipients, in whom dd‐cfDNA
is detected at a median of 0.21% by using the AlloSure® assay.11
Differences in baseline dd‐cfDNA levels may reflect differences in
the rate of cell turnover within the allograft. This is also in contrast
to the median dd‐cfDNA level of 0.16% in pAMR0 patients in the
Cedars‐Sinai study. This difference is likely due to the difference in
patient populations between the 2 cohorts; the stable patients in D‐
OAR were thought to be at low risk for AR and tended to have less
allograft injury than the patients in the Cedars‐Sinai study, who were
all allosensitized patients.
Prior studies have also shown that dd‐cfDNA levels may begin to
rise weeks to months before AR is diagnosed on endomyocardial bi‐
opsy.8,17 These elevated levels represent the early graft injury that
occurs before myocyte damage is apparent on histology. Surveillance
with dd‐cfDNA may therefore detect early rejection and thereby
trigger augmentation of immunosuppression to prevent a more se‐
vere rejection event that may result in irreversible graft damage.
This early detection of graft injury in the setting of a negative biopsy
may account for some of the false‐positive results seen in this study.
Similarly, the relatively low PPV of 8.9% for the detection of AR re‐
flects the low prevalence of rejection in this clinically stable patient

N=99
0.16%

N=11
0.50%

F I G U R E 5 Donor‐derived cell‐free DNA (dd‐cfDNA) correlates
with antibody‐mediated rejection (AMR) in the Cedars‐Sinai
study. Sample sizes and median dd‐cfDNA levels for samples
from patients with AMR grade pAMR0 and AMR grade ≥ pAMR1.
Samples with pAMR1 or higher have elevated levels of dd‐cfDNA

population. Patients were enrolled in the D‐OAR study while under‐
going routine AlloMap peripheral gene expression testing for rejec‐
tion surveillance. In general, patients who undergo AlloMap testing
tend to be “low risk” clinically—they have not had recent rejection
events and are not highly allosensitized. Only 2.2% of the biopsies
performed in D‐OAR patients were positive for ACR and 2.1% were
positive for AMR. The incidence of treated rejection in the first year
posttransplant, as reported by the International Society for Heart and
Lung Transplantation thoracic transplant registry, is currently 13%.1

by inclusion of an independent patient set (Cedars‐Sinai cohort) that

Early rejection events may have occurred in the first 2 months post‐

confirms the ability of dd‐cfDNA to detect AMR. dd‐cfDNA levels are

transplant, before patients were eligible to enroll in D‐OAR.

also correlated with the presence of graft dysfunction, especially in

Additionally, many patients were enrolled later than 2 months

patients with a large (≥25%) drop in LVEF. These results confirm the

posttransplant and were tested over several years, during which

hypothesis that cell‐free DNA is released from cells within the donor

time the prevalence of AR is very low. The distribution of tests was

organ during episodes of significant graft injury. Reassuringly, episodes

81% in the first year and 14% in the second year (Figure S1).

of grade 1R (mild) ACR, which is usually considered clinically irrelevant,

Another consideration when evaluating dd‐cfDNA test perfor‐

were not correlated with elevated dd‐cfDNA levels. These results

mance is that endomyocardial biopsy is not a true “gold standard” for

seem to confirm the clinical suspicion that grade 1R (mild) ACR does

the diagnosis of AR. There are many limitations of the biopsy, including

not result in significant graft injury. The natural progression of ACR

sampling error and interobserver variability in biopsy interpretation.

grade 1R is not well defined, but we observed that the majority of pa‐

A prior study that compared expert panel (core) biopsy interpretation

tients did not progress to clinically overt rejection. In another recent

with locally assigned grades showed that 52% of local ≥ 2R ACRs were

study,16 the composite outcome of death, retransplant, rejection with

assigned lower grades (no significant rejection) by the panel and that

hemodynamic compromise (defined as LVEF ≤ 40% or a drop ≥ 25%

overall agreement for the diagnosis of ACR between panel and local

compared with baseline or use of inotropic drugs or mechanical sup‐

reads was only 28.4%.18 dd‐cfDNA, which directly assesses damage to

port), and nonspecific graft dysfunction (hemodynamic compromise

the transplanted organ, may therefore be a more objective and accu‐

without evidence of rejection) occurred in 103 patients during follow‐

rate assay for graft injury than the traditional biopsy.

up, and the occurrence of this composite endpoint at 1, 5, and 10 years

The dd‐cfDNA noninvasive monitoring test can reduce biopsy

was 4%, 15%, and 23%, respectively, whereas grade 1R ACR was found

utilization and save health care costs, as has been modeled for the

in 40.7% (456/1118) of biopsies performed between 2 and 6 months

AlloMap test.19 It has been estimated that the cost‐effectiveness of

posttransplant.

a blood‐based biomarker compared with endomyocardial biopsy for
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In summary, this study establishes the performance of the dd‐

of $27,244 and quality adjusted life year gain of 0.046 on average

cfDNA assay to detect acute rejection and graft dysfunction after

during the first 5 years posttransplant. 20

HT in a large and diverse patient cohort in the United States. These

The limitations of this study include (1) the change in protocol
designed to increase the number of rejection events. To adjust for

results set the stage for subsequent clinical utility studies of the dd‐
cfDNA assay in HT patient management.

this change in study methods, we have analyzed the “surveillance”
and “for‐cause” results separately. (2) Concurrent dd‐cfDNA re‐
sults were available for only 58% of biopsy specimens. (3) The only

AC K N OW L E D G M E N T S

analyte quantified by the assay used in this study is the fraction of

The authors would like to thank Preethi Prasad and Theresa Wolf at

dd‐cfDNA in the total cfDNA in the recipient's plasma. It is possi‐
ble that conditions unrelated to AR, such as increased turnover or
death of recipient cells (as seen in trauma21 and sepsis22), can result
in elevated total cfDNA levels and thereby reduce the donor frac‐
tion. Nevertheless, dd‐cfDNA levels have previously been shown
by multiple independent groups to be elevated in the setting of AR

CareDx, Inc., the research coordinators at the participating trans‐
plant centers for supporting the study conduct as well as sample and
data collection, and the many heart transplant recipients who self‐
lessly participated in this study.

after heart, 8-10 kidney,7,11 liver,7,23,24 and lung 25 transplant. (4) The

D I S C LO S U R E

Cedars‐Sinai cohort was small and was from a single center. Also,

The authors of this manuscript have conflicts of interest to disclose

only AMR events were observed in this cohort, likely due to the
patient selection criteria. However, the results are consistent with
the D‐OAR study and confirm the ability of dd‐cfDNA to detect
graft damage. (5) With the recommended cutoff of 0.2%, there
will be some false‐positive results; however, the potential negative
impact of these may be mitigated if the clinician considers other
clinical information about the patient (including symptoms, signs,
and imaging results) before deciding whether a biopsy should be

as described by the American Journal of Transplantation. Dr Khush
is an advisor to CareDx and has received research support from
CareDx. Drs Yee, Woodward, and Hiller are employees of CareDx.
Drs Hall and Kobashigawa serve as co‐PIs and as advisors (consult‐
ants) to CareDx. Drs Pinney, Kao, Alharethi, DePasquale, Ewald,
Berman, and Kanwar were co‐PIs in the DOAR study. Dr Patel has
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performed.
dd‐cfDNA is measured in plasma from a blood draw and there‐
fore can be performed frequently after HT. This, combined with
the potential of the assay to detect early signs of graft damage, 8,17
opens the door to more personalized titration of immunosuppres‐

DATA AVA I L A B I L I T Y S TAT E M E N T
The data that support the findings of this study are available from
the corresponding author upon reasonable request.

sive therapies. Immunosuppressive medications such as cortico‐
steroids and calcineurin inhibitors could potentially be weaned
faster in patients with no evidence of graft injury and augmented
in patients who demonstrate a rise in dd‐cfDNA levels. Thus, more
effective immunosuppression could be administered to recipients
at higher risk of AR, whereas the side effects and toxicities of these
medications could be avoided in stable patients. Additionally, this
test may be performed if there is clinical suspicion for rejection
or graft injury, before deciding on the need for endomyocardial
biopsy. HT recipients may present with nonspecific symptoms,
such as dyspnea, that could be due to graft dysfunction or op‐
portunistic infection. The dd‐cfDNA result may thereby help to
focus subsequent diagnostic testing. This is especially useful in
patients who are receiving anticoagulation therapy, with anatomic
challenges, or with other contraindications to biopsy procedures.
As with all laboratory tests, clinical evaluation of the patient must
be factored into the interpretation of test results. The dd‐cfDNA
test results may not eliminate the need for biopsy, but a high level
may increase the probability of a positive biopsy result and would
provide further justification for initiating clinical treatment of AR.
The high NPV of the assay, on the other hand, would reduce the
need for biopsies in patients with low suspicion for AR.
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